Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: Impact of institutions

Breast

Volumn 23, Issue 2, 2014, Pages 165-169

  Fiteni, Frederic ^a   Villanueva, Cristian ^a   Bazan, Fernando ^a   Perrin, Sophie ^a   Chaigneau, Loic ^a   Dobi, Erion ^a   Montcuquet, Philippe ^a   Cals, Laurent ^a   Meneveau, Nathalie ^a   Nerich, Virginie ^a   Limat, Samuel ^a   Pivot, Xavier ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Breast cancer; Metastatic treatment; Trastuzumab

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE INTERVAL; FOLLOW UP; FRANCE; GENERAL HOSPITAL; HOSPITAL; HUMAN; INSTITUTIONAL CARE; LIVER METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SPECIALIZED HOSPITAL; SURVIVAL RATE; SURVIVAL TIME; BREAST NEOPLASMS; FEMALE; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84895421996     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.12.003     Document Type: Article

References (24)

1. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 12 mai 1989, 244(4905):707-712.
2. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-Positive metastatic breast cancer administered as first-line treatment: the M77001 study group. JClin Oncol 7 janv 2005, 23(19):4265-4274.
3. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 15 mars 2001, 344(11):783-792.
4. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A.B., et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. JClin Oncol Off J Am Soc Clin Oncol 20 janv 2011, 29(3):264-271.
5. Valero V., Forbes J., Pegram M.D., Pienkowski T., Eiermann W., von Minckwitz G., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. JClin Oncol Off J Am Soc Clin Oncol 10 janv 2011, 29(2):149-156.
6. Wardley A.M., Pivot X., Morales-Vasquez F., Zetina L.M., de Fátima Dias Gaui M., Reyes D.O., et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. JClin Oncol Off J Am Soc Clin Oncol 20 févr 2010, 28(6):976-983.
7. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. JClin Oncol Off J Am Soc Clin Oncol 20 nov 2009, 27(33):5538-5546.
8. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. JClin Oncol Off J Am Soc Clin Oncol 20 nov 2009, 27(33):5529-5537.
9. Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C.G., et al. Aphase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat déc 2008, 112(3):533-543.
10. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. NEngl J Med 28 déc 2006, 355(26):2733-2743.
11. Von Minckwitz G., Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. JClin Oncol Off J Am Soc Clin Oncol 20 avr 2009, 27(12):1999-2006.
12. Dawood S., Broglio K., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. JClin Oncol Off J Am Soc Clin Oncol 1 janv 2010, 28(1):92-98.
13. Andreopoulou E., Hortobagyi G.N. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. JClin Oncol Off J Am Soc Clin Oncol 1 aoÛt 2008, 26(22):3660-3662.
14. Hortobagyi G.N., Smith T.L., Legha S.S., Swenerton K.D., Gehan E.A., Yap H.Y., et al. Multivariate analysis of prognostic factors in metastatic breast cancer. JClin Oncol Off J Am Soc Clin Oncol déc 1983, 1(12):776-786.
15. Vernooij F., Heintz A.P.M., Coebergh J.-W., Massuger L.F.A.G., Witteveen P.O., van der Graaf Y. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol mars 2009, 112(3):455-461.
16. Vernooij F., Heintz A.P.M., Witteveen P.O., van der Heiden-van der Loo M., Coebergh J.-W., van der Graaf Y. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. JNatl Cancer Inst 19 mars 2008, 100(6):399-406.
17. Vernooij F., Heintz P., Witteveen E., van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol juin 2007, 105(3):801-812.
18. Nerich V., Limat S., Demarchi M., Borg C., Rohrlich P.S., Deconinck E., et al. Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors. Int J Med Inf oct 2010, 79(10):699-706.
19. Gianni L., Romieu G.H., Lichinitser M., Serrano S.V., Mansutti M., Pivot X., et al. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. JClin Oncol Off J Am Soc Clin Oncol 10 mai 2013, 31(14):1719-1725.
20. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H.S., Sledge G., Aktan G., et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. JClin Oncol Off J Am Soc Clin Oncol 20 juill 2012, 30(21):2585-2592.
21. Pivot X., Zurawski B., Allerton R., Fabi A., Ciruelos E., Parikh R., et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with HER2-positive metastatic breast cancer. Eur Soc Med Oncol 2012, LBA 11.
22. Baselga J., Cortés J., Kim S.-B., Im S.-A., Hegg R., Im Y.-H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 12 janv 2012, 366(2):109-119.
23. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. NEngl J Med 8 nov 2012, 367(19):1783-1791.
24. Gelmon K., Boyle F., Kaufman B., Huntsman D., Manikhas A., Di Leo A., et al. Randomized controlled trial comparing taxane-based chemotherapy with lapatinib or trastuzmab as first-line therapy for women with HER2-positive metastatic breast cancer. Am Soc Clin Oncol 2012, 30(15). LBA 671.